Sten Madsbad Selected Research

Weight Loss (Weight Reduction)

1/2022	Macrophage activation marker sCD163 is associated with liver injury and hepatic insulin resistance in obese patients before and after Roux-en-Y gastric bypass.
1/2022	Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial.
1/2022	Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes.
1/2022	Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: a randomised controlled trial.
1/2022	Weight-loss induced by carbohydrate restriction does not negatively affect health-related quality of life and cognition in people with type 2 diabetes: A randomised controlled trial.
1/2021	Genetic markers of abdominal obesity and weight loss after gastric bypass surgery.
1/2021	Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
1/2021	The role of GLP-1 in postprandial glucose metabolism after bariatric surgery: a narrative review of human GLP-1 receptor antagonist studies.
1/2020	Intestinal sensing and handling of dietary lipids in gastric bypass-operated patients and matched controls.
1/2020	The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sten Madsbad Research Topics

Disease

115	Type 2 Diabetes Mellitus (MODY) 10/2022 - 03/2002
72	Insulin Resistance 01/2022 - 03/2002
64	Weight Loss (Weight Reduction) 01/2022 - 01/2006
44	Obesity 05/2022 - 01/2006
30	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2022 - 07/2002
24	Body Weight (Weight, Body) 01/2022 - 06/2004
14	Hypoglycemia (Reactive Hypoglycemia) 10/2019 - 09/2003
12	Overweight 01/2022 - 04/2002
12	Lipodystrophy 08/2007 - 10/2003
11	Inflammation (Inflammations) 08/2021 - 10/2008
9	Glucose Intolerance 03/2015 - 07/2003
8	Coronary Artery Disease (Coronary Atherosclerosis) 01/2019 - 07/2014
7	Cardiovascular Diseases (Cardiovascular Disease) 05/2021 - 08/2003
7	Hyperglycemia 01/2020 - 07/2002
6	Morbid Obesity 01/2021 - 11/2016
6	Weight Gain 01/2020 - 06/2004
6	Hyperinsulinism (Hyperinsulinemia) 11/2018 - 03/2006
5	Diabetes Complications 01/2022 - 04/2002
5	Bone Resorption 01/2022 - 08/2015
5	Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal) 11/2020 - 09/2008
5	Nausea 01/2020 - 11/2008
5	Hypertension (High Blood Pressure) 05/2014 - 02/2005
5	Diabetes Mellitus 11/2008 - 03/2005
4	Myocardial Infarction 05/2019 - 05/2006
4	Birth Weight (Birth Weights) 01/2008 - 08/2005
4	Chronic Pancreatitis 12/2007 - 09/2003
3	Heart Failure 10/2022 - 01/2019
3	Non-alcoholic Fatty Liver Disease 01/2022 - 11/2020
3	Metabolic Diseases (Metabolic Disease) 09/2019 - 10/2015
3	Stroke (Strokes) 05/2019 - 01/2016
3	HIV Infections (HIV Infection) 02/2010 - 12/2004
2	Fibrosis (Cirrhosis) 08/2021 - 11/2020
2	Alcoholic Fatty Liver 08/2021 - 05/2014
2	Genetic Risk Score 01/2021 - 01/2019
2	Atherosclerosis 01/2019 - 08/2013
2	Hyperlipidemias (Hyperlipidemia) 09/2018 - 07/2002

Drug/Important Bio-Agent (IBA)

96	Glucose (Dextrose)FDA LinkGeneric 10/2022 - 03/2002
76	Insulin (Novolin)FDA Link 01/2022 - 03/2002
48	Glucagon-Like Peptide 1 (GLP 1)IBA 10/2022 - 03/2002
31	Liraglutide FDA Link 01/2022 - 06/2004
25	Hormones (Hormone)IBA 01/2022 - 12/2006
20	Metformin (Glucophage)FDA LinkGeneric 01/2022 - 04/2002
20	Glucagon (Glukagon)FDA Link 01/2022 - 03/2002
16	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2003
16	IncretinsIBA 01/2021 - 12/2006
15	CarbohydratesIBA 01/2022 - 11/2015
15	Glucagon-Like Peptide-1 ReceptorIBA 01/2020 - 02/2015
14	LipidsIBA 08/2021 - 02/2005
13	Peptides (Polypeptides)IBA 01/2021 - 08/2005
10	Glucagon-Like Peptide-1 Receptor AgonistsIBA 02/2021 - 07/2008
8	Nonesterified Fatty Acids (NEFA)IBA 01/2019 - 03/2002
7	C-PeptideIBA 10/2018 - 03/2002
6	Triglycerides (Triacylglycerol)IBA 01/2022 - 07/2009
6	Fatty Acids (Saturated Fatty Acids)IBA 01/2022 - 02/2006
6	Blood Glucose (Blood Sugar)IBA 01/2020 - 08/2003
6	Hypoglycemic Agents (Hypoglycemics)IBA 10/2019 - 06/2004
6	Pharmaceutical PreparationsIBA 01/2017 - 04/2002
5	Dietary Carbohydrates (Carbohydrate, Dietary)IBA 01/2022 - 09/2018
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 04/2007
5	AdiponectinIBA 01/2019 - 11/2003
5	Messenger RNA (mRNA)IBA 01/2016 - 10/2005
5	Growth Hormone (Somatotropin)IBA 11/2015 - 01/2004
4	Biphasic InsulinsIBA 01/2022 - 05/2002
4	Mitochondrial DNA (mtDNA)IBA 01/2022 - 09/2005
4	Exenatide (Byetta)FDA Link 01/2020 - 07/2008
4	semaglutideIBA 01/2020 - 01/2017
4	CreatinineIBA 07/2017 - 11/2004
4	Insulin-Like Growth Factor I (IGF-1)IBA 02/2010 - 01/2004
4	phospholipid emulsion soybean oil (Intralipid)IBA 10/2005 - 06/2003
3	TesofensineIBA 05/2022 - 11/2008
3	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 09/2005
3	Collagen Type I (Type I Collagen)IBA 11/2021 - 08/2015
3	activin AIBA 01/2021 - 12/2019
3	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2021 - 11/2008
3	FollistatinIBA 01/2021 - 12/2019
3	Type 4 Melanocortin Receptor (Melanocortin-4 Receptor)IBA 01/2020 - 07/2018
3	C-Reactive ProteinIBA 01/2019 - 10/2008
3	Orlistat (Xenical)FDA Link 02/2011 - 01/2006
3	Pioglitazone (Actos)FDA Link 11/2007 - 08/2004
2	Angiotensin Receptor AntagonistsIBA 10/2022 - 11/2004
2	nasIBA 08/2021 - 11/2020
2	dulaglutideIBA 01/2021 - 04/2016
2	Amino Acids FDA Link 11/2020 - 01/2019
2	Nucleic AcidsIBA 09/2020 - 01/2020
2	MineralsIBA 01/2020 - 08/2015
2	Phospholipids (Phosphatides)FDA LinkGeneric 09/2019 - 02/2006
2	Lipoproteins (Lipoprotein)IBA 09/2019 - 01/2019
2	ProcollagenIBA 01/2019 - 08/2015
2	Cholecystokinin (Pancreozymin)IBA 12/2018 - 09/2018

Therapy/Procedure

44	Gastric Bypass (Roux-en-Y Gastric Bypass) 01/2022 - 02/2009
39	Therapeutics 01/2022 - 04/2002
19	Bariatric Surgery 01/2022 - 02/2014
13	Glycemic Control 01/2021 - 05/2002
11	Caloric Restriction 01/2022 - 01/2006
8	High-Protein Diet 01/2022 - 01/2018
7	Highly Active Antiretroviral Therapy (HAART) 08/2007 - 11/2003
6	Gastrectomy 08/2021 - 10/2014
4	Carbohydrate-Restricted Diet (Low Carbohydrate Diet) 01/2022 - 01/2017
3	Subcutaneous Injections 01/2020 - 09/2003
3	Injections 09/2016 - 07/2008